Skip to main
IGC
IGC logo

IGC Stock Forecast & Price Target

IGC Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

IGC Pharma Inc. is focused on developing cannabinoid-based formulations for various medical conditions, including Alzheimer's disease, where its investigational drug assets have exhibited potential efficacy in addressing key disease hallmarks such as plaques and tangles. With an updated valuation indicating a significant upside based on a net present value analysis, the stock presents an attractive investment opportunity. Furthermore, the expected release of additional positive data regarding its drug candidates, particularly IGC-AD1, is anticipated to further enhance the stock's appeal and drive future growth.

Bears say

IGC Pharma Inc reported a net loss of $1.6 million for the period, translating to an earnings per share (EPS) of $(0.02), which aligns with prior estimates but indicates a continued struggle to achieve profitability. The company faces significant risks, including balance sheet and liquidity concerns, the uncertain outcome of clinical trials for its product candidates, and challenges in obtaining regulatory approvals and commercializing its products. Coupled with the competitive landscape and evolving investor sentiment towards biotech stocks, these factors contribute to a negative outlook on IGC Pharma's financial stability and future growth potential.

IGC has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About India Globalization Capital (IGC) Forecast

Analysts have given IGC a Strong Buy based on their latest research and market trends.

According to 2 analysts, IGC has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

India Globalization Capital (IGC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.